Abstract:The most commonly used influenza vaccines are made from inactivated viruses and are administered via the intramuscular route. Although these vaccines can protect from severe lower respiratory tract disease, they do not completely prevent virus replication in the upper respiratory tract, and this may lead to virus excretion and dissemination. Therefore, nasally administered live-attenuated influenza vaccines (LAIV) that induce mucosal immunity have been developed, but finding an optimal balance between sufficient attenuation and immunogenicity remained challenging. These problems apply to both human and swine influenza vaccines. We have recently developed an LAIV candidate based on the 2009 pandemic H1N1 virus which encodes a truncated NS1 protein and lacks PA-X protein expression (NS1(1-126)-ΔPAX). This virus showed a blunted replication and elicited a strong innate immune response. In the present study, we took advantage of the pig animal model to evaluate this vaccine candidate and to identify a strategy for its improvement. Nasal infection of pigs with the NS1(1-126)-ΔPAX LAIV candidate did not cause disease but was associated with prolonged virus shedding from the upper respiratory tract. To increase safety of the vaccine candidate, we developed a novel prime/boost vaccination strategy consisting of a haemagglutinin-encoding propagation-defective vesicular stomatitis virus replicon vaccine for primary immunization via the intramuscular route, and the NS1(1-126)-ΔPAX LAIV for secondary immunization via the nasal route. This immunization strategy significantly reduced LAIV shedding, increased the production of specific serum IgG, neutralizing antibodies, Th1 memory cells, and induced virus-specific mucosal IgG and IgA. Of particular note, the immune response induced by this vaccination strategy completely blocked replication of the homologous challenge virus in the respiratory tract, indicating that sterilizing immunity was achieved. In summary, our novel intramuscular prime/intranasal boost vaccine combines the features of high efficacy and safety which are urgently needed to combat influenza epidemics and pandemics.

Immediate and broad-spectrum protection against heterologous and heterotypic lethal challenge in mice by live influenza vaccine

Intradermal vaccination of live attenuated influenza vaccine protects mice against homologous and heterologous influenza challenges

Protective efficacy of intranasally administered bivalent live influenza vaccine and immunological mechanisms underlying the protection

A Host-Restricted Self-Attenuated Influenza Virus Provides Broad Pan-Influenza A Protection in a Mouse Model

Sequential immunization with chimeric hemagglutinin ΔNS1 attenuated influenza vaccines induces broad humoral and cellular immunity

Ns-Based Live Attenuated H1n1 Pandemic Vaccines Protect Mice and Ferrets

A Chymotrypsin-Dependent Live-Attenuated Influenza Vaccine Provides Protective Immunity against Homologous and Heterologous Viruses

Recombinant influenza A virus hemagglutinin HA2 subunit protects mice against influenza A(H7N9) virus infection

Intramuscular prime/intranasal boost vaccination to induce sterilizing immunity against influenza A virus infection

Engineered probiotic Escherichia coli elicits immediate and long-term protection against influenza A virus in mice

Induction of heterosubtypic immunity to influenza virus by intranasal immunization

Anti-viral immunity induced by recombinant nucleoprotein of influenza A virus. II. Protection from influenza infection and mechanism of protection

Evaluation of a novel intramuscular prime/intranasal boost vaccination strategy against influenza in the pig model

Broad spectrum immunity against influenza viruses elicited by intranasal vaccination with a new recombinant subunit vaccine (VAC2P.924)

Intranasal immunization with formalin-inactivated virus vaccine induces a broad spectrum of heterosubtypic immunity against influenza A virus infection in mice

Intranasal hemagglutinin protein boosters induce robust mucosal immunity and cross-protection against influenza A viral challenge

Mechanisms of Broad Cross-Protection Provided by Influenza Virus Infection and Their Application to Vaccines

Early mucosal events promote distinct mucosal and systemic antibody responses to live attenuated influenza vaccine

Evaluation of the humoral and cellular immune responses elicited by the live attenuated and inactivated influenza vaccines and their roles in heterologous protection in ferrets.

Protective efficacy of a novel recombinant influenza virus carrying partial human metapneumovirus F protein epitopes

A recombinant protein containing influenza viral conserved epitopes and superantigen induces broad-spectrum protection